LRRK2 and Parkinson disease: Using this assay, we found that both G2019S LRRK2 PD patient- and iPD patient-derived peripheral blood mononuclear cells displayed increased mtDNA damage compared with controls, including in iPD patients with acute washout of PD-related medications.